Liquidia Corporation
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Roger A. Jeffs
- Full Time Employees
- 170
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 419 Davis Drive Morrisville NC United States of America 27560
- IPO Date
- Jul 26, 2018
- CIK
- 0001819576
- Website
- liquidia.com
- Similar Companies
- Business
- Liquidia Corporation Liquidia Corporation (LQDA) is a biopharmaceutical company that develops, manufactures, and commercializes products addressing unmet needs in rare cardiopulmonary diseases, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD); its core offerings center on YUTREPIA, an inhaled dry powder formulation of treprostinil, alongside investigational therapies such as L606, a liposomal sustained-release formulation of treprostinil licensed from Pharmosa Biopharm Inc., and references to related products like Yutopia for inhalation and generic treprostinil options, all leveraging proprietary PRINT particle engineering technology for precise drug particle production. Founded in 2004 and headquartered in Morrisville, North Carolina, the company operates primarily in the United States through wholly owned subsidiaries Liquidia Technologies, Inc. and Liquidia PAH, LLC, targeting patients with rare respiratory conditions via innovative drug delivery systems that enhance convenience and efficacy. Recent developments include a $67.5 million common stock financing in September 2024 comprising a public offering and private placement with Caligan Partners LP, plus a $32.5 million advance under a fifth amendment to its Revenue Interest Financing Agreement with HealthCare Royalty, bringing total non-dilutive funding to $100 million and extending the agreement term to 2031 while supporting YUTREPIA commercialization, pediatric trials, and L606 advancement ahead of expected 2025 launch post-FDA tentative approval for PAH and PH-ILD; third quarter 2025 results highlighted launch momentum for YUTREPIA and improved profitability.
Are You Looking for a Top Momentum Pick? Why Liquidia Corporation (LQDA) is a Great Choice
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
4 Low-Beta Stocks for a Steadier Portfolio: LQDA, XOM, VLO & FANG
Earnings Estimates Moving Higher for Liquidia Corporation (LQDA): Time to Buy?
Liquidia Corporation (LQDA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
What to Know About This Fund’s $15.5 Million Sale of Liquidia as Shares Skyrocket Nearly 260%
Best Momentum Stocks to Buy for May 13th
New Strong Buy Stocks for May 13th
These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results
Liquidia: Yutrepia's Launch Momentum Is Approaching A Ceiling (Rating Downgrade)
Liquidia Corporation (LQDA) Q1 2026 Earnings Call Transcript
Liquidia Q1 Earnings Call Highlights
Liquidia Corporation (LQDA) Surpasses Q1 Earnings and Revenue Estimates
Liquidia Corporation Reports First Quarter 2026 Financial Results
Best Low-Beta Stocks to Own Right Away: LQDA, CBOE, VLO & FANG
Liquidia Corporation to Participate in Upcoming Investor Conferences
New Strong Buy Stocks for May 6th
Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026
This Drug Stock Nears A Buy Point, With Profit Set To Explode
Liquidia's (LQDA) CEO Sells 53,000 Shares for $2.1 Million